(2016), treatment with GLP-1 analog liraglutide significantly improved histological scores, colon weight/length ratio, and reduced inflammatory cytokines and chemokines such as CCL20, IL-33, and IL-22
As a result of taking semaglutide GLP-1, participants saw greater improvements in body mass index, waist circumference, blood pressure, and blood sugar levels than those taking placebos
The risk was calculated using multivariate logistic regression analysis and after adjusted for confounders such as high BMI and smoking
Unfortunately, for some people, this can result in super negative side effects like nausea, vomiting, and diarrhea - one study reported that 50% of patients taking GLP-1 agonists experienced nausea while taking them